Skip to content
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Menu
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Innovative Treatments for Liver & Pancreatic Tumors
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Platform
    • Drug Delivery Technology
  • Pipeline
    • Our Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • The Trisalus Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Back to Leadership
  • OUR TEAM

Ripal Gandhi, MD

  • Scientific Advisory Board Member

Dr. Ripal Gandhi did his undergraduate studies at Northwestern University and Harvard University. He graduated summa cum laude (highest honors). He received his degree in medicine from Northwestern University Medical School, where he also graduated with honors. Following medical school, he completed a surgical internship at Cornell University Medical Center and New York Presbyterian Hospital. He completed his residency training and fellowship at UCLA Medical Center. Currently, he is an associate clinical professor at the University of South Florida School of Medicine and FIU Herbert Wertheim College of Medicine. Ripal regularly trains other physicians in various vascular/endovascular, interventional radiology, and interventional oncology techniques.

Because of his interest in discovering new therapies, Ripal also dedicated an entire year to biomedical research at the renowned Memorial Sloan-Kettering Cancer Center in New York. At Sloan-Kettering, he investigated chemoembolization and other minimally invasive therapies for liver cancer and other malignancies. He also served as a research fellow at the National Institutes of Health (NIH). He has published his findings in several scientific journals, including the Journal of Vascular and Interventional Radiology, Journal of Vascular Surgery, Vascular Medicine, Interventional Cardiology, and Journal of the American College of Surgeons. He also authored several textbook chapters and presented his research at national and international meetings.

Prior to joining Miami Cardiac & Vascular Institute, he was an international visiting scholar at Asan Medical Center/University of Ulsan Medical School in Seoul, South Korea. As an international scholar, he gave several lectures and furthered his expertise in innovative minimally invasive therapies.

Ripal is the recipient of multiple awards, including the American College of Physicians Certificate of Merit for Outstanding Performance in Medicine, America’s Best Physicians, America’s Most Honored Doctors, Compassionate Doctor Award, Leading Physicians of the World, and Top 100 Health Professionals Distinction Award. In addition, he was recently honored with the Patients’ Choice Recognition Award, given to physicians most highly regarded by their patients. He is also a fellow of the Society for Vascular Medicine and a fellow of the Society of Interventional Radiology.

He is the co-author of the textbook Interventional Oncology which was recently published. In addition to being an expert in endovascular therapy and vascular disease, Dr. Gandhi is one of the interventional oncologists at Miami Cancer Institute and has expertise in minimally invasive therapies for cancer. He is a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).

© 2024 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL